المؤلفون: Masamichi Kurosaki, Tetsuji Uno, Kohei Shomori, Atsushi Kambe, Shinji Kondo, Yuichiro Nagao, Satoko Nakada, Makoto Sakamoto, Michiharu Tanabe

المصدر: Brain Tumor Pathology. 37:165-170

مصطلحات موضوعية: Male, Cancer Research, Pathology, medicine.medical_specialty, Solitary fibrous tumor, Radiosurgery, Neurosurgical Procedures, 03 medical and health sciences, Fatal Outcome, Rare Diseases, 0302 clinical medicine, medicine, Humans, Dedifferentiated Solitary Fibrous Tumor, Aged, Aged, 80 and over, Hemangiopericytoma, Osteosarcoma, Brain Neoplasms, business.industry, Clinical course, Neoplasms, Second Primary, Histology, Cytoreduction Surgical Procedures, General Medicine, Cell Dedifferentiation, medicine.disease, Repressor Proteins, Oncology, Tumor progression, Solitary Fibrous Tumors, 030220 oncology & carcinogenesis, Disease Progression, Neurology (clinical), Neurosurgery, Gene Fusion, STAT6 Transcription Factor, business, 030217 neurology & neurosurgery

الوصف: Solitary fibrous tumor/hemangiopericytoma is a mesenchymal tumor that originates from a common NAB2-STAT6 fusion gene and is known to very rarely demonstrate dedifferentiation in the pattern of local recurrence or distant metastasis. Here we describe for the first time a rare case of intracranial dedifferentiated solitary fibrous tumor/hemangiopericytoma with osteosarcoma components that developed in an 84-year-old man after frequent gamma knife radiosurgery over a 14-year period. We performed tumor-debulking and gamma knife radiosurgery, but unfortunately the patient died shortly after the development of dedifferentiation. There is no established treatment for dedifferentiated cases due to the rare histology and limited published data, and therefore further accumulation of histological and genetic profiles is necessary to develop novel target gene therapies.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17945682e9d5276938da8f075e1b5bdTest
https://doi.org/10.1007/s10014-020-00374-yTest

المؤلفون: Sohsuke Yamada, Takayuki Nojima, Satoko Nakada, Hideaki Iizuka, Akihiro Shioya, Osamu Tachibana, Yasuo Sasagawa, Xin Guo, Nozomu Kurose

المصدر: Brain Tumor Pathology. 36:7-13

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Time Factors, VEGF receptors, Gene Expression, World Health Organization, Disease-Free Survival, Receptor tyrosine kinase, Meningioma, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Meningeal Neoplasms, medicine, Humans, Progression-free survival, Genetic Association Studies, Aged, Neoplasm Staging, Aged, 80 and over, Univariate analysis, Tumor size, biology, business.industry, General Medicine, Middle Aged, Who grade, medicine.disease, Immunohistochemistry, Vascular Endothelial Growth Factor Receptor-2, 030220 oncology & carcinogenesis, embryonic structures, Disease Progression, biology.protein, Female, Neurology (clinical), Neoplasm Recurrence, Local, business, 030217 neurology & neurosurgery

الوصف: WHO grade II/III meningiomas recur frequently and there is currently no established molecular target therapy for meningioma. No previous studies have revealed the association between receptor tyrosine kinases (RTKs) and the recurrence of meningiomas. This study aims to elucidate the association between RTKs and the clinicopathological characteristics and recurrence of meningioma. We investigated the immunohistochemical expression of RTKs (VEGFR-1/2/3, PDGFR-alpha/beta and c-Kit) in 81 meningiomas (WHO grade I, n = 64, WHO grade II/III, n = 17) in 74 patients. Immunohistochemistry revealed that 29 WHO grade I (45%), 10 WHO grade II (77%), and 4 WHO grade III (100%) tumors were VEGFR-2-positive, and that the VEGFR-2 expression was significantly correlated with the WHO grade. In univariate analyses to investigate the clinicopathological factors associated with recurrence, Simpson grade IV/V resection, a larger tumor size, a high VEGFR-2 expression level, WHO grade II/III, a high Ki-67 expression level, and the non-expression of PgR were identified as significant factors. Furthermore, patients with VEGFR-2-positive meningiomas showed significantly shorter progression-free survival. In the multivariate analysis, WHO grade II/III and the location were significantly associated with recurrence. In conclusion, our study suggests that VEGFR-2 inhibitors might be one of the best candidates for molecular therapy against recurrent meningiomas.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3842a2c21e363dfea34604a7baf16ffTest
https://doi.org/10.1007/s10014-018-0332-1Test

المؤلفون: Takayuki Nojima, Hiroshi Minato, Satoko Nakada

المصدر: Brain tumor pathology. 33(3)

مصطلحات موضوعية: Adult, Male, endocrine system, Cancer Research, Solitary fibrous tumor, Pathology, medicine.medical_specialty, Time Factors, Adolescent, NAB2/STAT6 Fusion Gene, Biology, Metastasis, Fusion gene, 03 medical and health sciences, Exon, Young Adult, 0302 clinical medicine, parasitic diseases, medicine, Meningeal Neoplasms, Humans, Child, Genetic Association Studies, Aged, Hemangiopericytoma, Aged, 80 and over, NAB2, integumentary system, Meninges, Genetic Variation, General Medicine, respiratory system, Middle Aged, medicine.disease, Repressor Proteins, medicine.anatomical_structure, Oncology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Solitary Fibrous Tumors, Cancer research, Female, Neurology (clinical), Gene Fusion, STAT6 Transcription Factor, 030217 neurology & neurosurgery, Follow-Up Studies

الوصف: Investigations on the NAB2–STAT6 fusion gene in solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) have increased since its discovery in 2013. Although several SFTs reported without NAB2–STAT6 fusion gene analysis, we reviewed 546 SFTs/HPCs with NAB2–STAT6 fusion gene analysis in this study and investigated differences between the gene variants. In total, 452 cases tested positive for the NAB2–STAT6 fusion gene, with more than 40 variants being detected. The most frequent of these were NAB2 exon 6-STAT6 exon 16/17/18 and NAB2 exon 4-STAT6 exon 2/3, with the former occurring most frequently in SFTs in meninges, soft tissues, and head and neck; the latter predominated in SFTs in the pleura and lung. There was no difference between the histology of SFTs and fusion gene variants. A follow-up analysis of SFTs showed that 51 of 202 cases had a recurrence, with 18 of 53 meningeal SFTs having a local recurrence and/or metastasis within 0–19 years. In meninges and soft tissue, SFTs with the NAB2 exon 6-STAT6 exon 16/17/18 tended to recur more frequently than SFTs with the NAB2 exon 4-STAT6 exon 2/3. Clinicopathological data, including yearly follow-ups, are required for meningeal SFTs/HPCs to define the correlation of variants of NAB2–STAT6 fusion gene.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43b706ffaf4ef712579d5841c3bb2c7cTest
https://pubmed.ncbi.nlm.nih.gov/27271270Test

المؤلفون: Hiroko Ikeda, Takashi Kato, Hiroshi Minato, Takuya Akai, Norio Yamamoto, Tsutomu Takegami, Masako Kobayashi, Nozomu Kurose, Takayuki Nojima, Yasuo Sasagawa, Satoko Nakada

المصدر: Brain tumor pathology. 32(4)

مصطلحات موضوعية: Adult, Male, endocrine system, Cancer Research, Solitary fibrous tumor, Pathology, medicine.medical_specialty, Lung Neoplasms, Bone Neoplasms, NAB2/STAT6 Fusion Gene, Biology, Skull Base Neoplasms, Metastasis, Fusion gene, Exon, parasitic diseases, medicine, Humans, Nuclear atypia, Cerebellar Neoplasms, Aged, Hemangiopericytoma, Cranial Fossa, Middle, integumentary system, General Medicine, Exons, respiratory system, medicine.disease, Primary tumor, Immunohistochemistry, Repressor Proteins, Oncology, Cancer research, Female, Neurology (clinical), Gene Fusion, STAT6 Transcription Factor

الوصف: We present two cases of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma (HPC) with immunohistochemistry of STAT6 and analysis of NAB2–STAT6 fusion genes. Case 1 was a 37-year-old male with a left middle fossa tumor; case 2 was a 68-year-old female with a cerebellar tumor. They showed late metastasis to the lung or bone 8 or 13 years, respectively, after the first surgery. Histology of both primary and metastatic tumors showed a cellular hemangiopericytomatous pattern with nuclear atypia. The primary tumors showed nuclear staining of STAT6, but both metastatic tumors showed nuclear and cytoplasmic STAT6. DNA sequencing revealed two kinds of NAB2–STAT6 fusion genes. One consisted of exon 6 of NAB2, intron 6 of NAB2, and the middle of exon 17 of STAT6 (observed in the primary and metastatic tumors of case 1); the other consisted of exon 6 of NAB2 and the beginning of exon 17 of STAT6 (observed in the metastatic tumor of case 2). The primary tumor of case 2 had both fusion genes. To the best of our knowledge, we are the first to report NAB2–STAT6 fusion gene analysis in primary and metastatic meningeal SFT/HPCs and a case showed different fusion gene status in the metastatic tumor.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53f6bc7803924c6806c712f65d72bda6Test
https://pubmed.ncbi.nlm.nih.gov/25893823Test

المؤلفون: Yutaka Hayashi, Mitsutoshi Nakada, Tomohide Suzuki, Shingo Tanaka, Jun-ichiro Hamada, Tomoya Kamide, Seiji Yano, Yasuhiko Hayashi, Seiko Sawada-Kitamura, Satoko Nakada, Natsuki Furuyama

المصدر: Brain tumor pathology. 28(1)

مصطلحات موضوعية: Male, Cancer Research, Pathology, medicine.medical_specialty, Methyltransferase, Protoporphyrins, Methylation, Polymerase Chain Reaction, medicine, Biomarkers, Tumor, Humans, DNA Modification Methylases, Neuronavigation, medicine.diagnostic_test, Glial fibrillary acidic protein, biology, Brain Neoplasms, Tumor Suppressor Proteins, Magnetic resonance imaging, Histology, General Medicine, Aminolevulinic Acid, Middle Aged, Epithelioid Glioblastoma, DNA Repair Enzymes, Spectrometry, Fluorescence, Oncology, biology.protein, Immunohistochemistry, Histopathology, Neurology (clinical), Glioblastoma, Magnetic Resonance Angiography

الوصف: A 55-year-old man was admitted to our hospital complaining of left hemiparesis. Magnetic resonance imaging (MRI) showed a smooth ring-like enhanced cystic tumor in the right parietal lobe. He underwent gross total resection of the tumor under neuronavigation and 5-aminolevulinic acid (5-ALA) fluorescence guiding method. Histopathological examination of the tumor showed small cells formed epithelioid solid nests with some focus of duct-like structure. On the basis of the MRI and operative and histological findings, this tumor was diagnosed as a metastatic poorly differentiated carcinoma, although the primary cancer could not be detected by metastatic work-ups. Afterward, this tumor recurred repeatedly. Histopathological examination of specimen from the fourth surgery indicated that the tumor was a glioblastoma (GBM). In the review of the histology and immunohistochemistry of the first tumor, atypical fibrillary cells were seen between solid nests and positive for glial fibrillary acidic protein, therefore the tumor was retrospectively diagnosed as epithelioid GBM. We assessed whether the changes in histopathology were accompanied by changes in the methylation status of O6-methylguanine methyltransferase (MGMT) promoter and the status of 5-ALA fluorescence. The methylation status of the MGMT promoter was found to have changed from methylated to unmethylated and 5-ALA fluorescence became positive along with the histological change.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3096df06d3b8dbde74a117610c417b0Test
https://pubmed.ncbi.nlm.nih.gov/21188541Test

المؤلفون: Satoko Nakada, Hiroshi Minato, Takayuki Nojima

المصدر: Brain Tumor Pathology; Jul2016, Vol. 33 Issue 3, p169-174, 6p

مستخلص: Investigations on the NAB2-STAT6 fusion gene in solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) have increased since its discovery in 2013. Although several SFTs reported without NAB2-STAT6 fusion gene analysis, we reviewed 546 SFTs/HPCs with NAB2-STAT6 fusion gene analysis in this study and investigated differences between the gene variants. In total, 452 cases tested positive for the NAB2-STAT6 fusion gene, with more than 40 variants being detected. The most frequent of these were NAB2 exon 6-STAT6 exon 16/17/18 and NAB2 exon 4-STAT6 exon 2/3, with the former occurring most frequently in SFTs in meninges, soft tissues, and head and neck; the latter predominated in SFTs in the pleura and lung. There was no difference between the histology of SFTs and fusion gene variants. A follow-up analysis of SFTs showed that 51 of 202 cases had a recurrence, with 18 of 53 meningeal SFTs having a local recurrence and/or metastasis within 0-19 years. In meninges and soft tissue, SFTs with the NAB2 exon 6-STAT6 exon 16/17/18 tended to recur more frequently than SFTs with the NAB2 exon 4-STAT6 exon 2/3. Clinicopathological data, including yearly follow-ups, are required for meningeal SFTs/HPCs to define the correlation of variants of NAB2-STAT6 fusion gene. [ABSTRACT FROM AUTHOR]

: Copyright of Brain Tumor Pathology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)